Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

Source · https://www.globenewswire.com/news-release/2026/05/30/3303889/0/en/Mineralys-Therapeutics-Presents-New-Data-from-the-Phase-3-Launch-HTN-Trial-of-Lorundrostat-in-Participants-with-Hypertension-and-Chronic-Kidney-Disease-at-European-Meeting-on-Hyper.html

Read source

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

Search tags

What matters in this story

Lorundrostat demonstrated statistically significant and clinically meaningful blood pressure reductions in Phase 3 Launch-HTN trial participants with chronic kidney disease (CKD). — Positive Phase 3 data in a difficult-to-treat population increases the probability of regulatory approval and expands the drug's potential market size.

+0.60

Lorundrostat achieved a 52.2% placebo-adjusted reduction in urinary albumin-to-creatinine ratio (UACR) among CKD participants with albuminuria. — Reducing albuminuria suggests the drug provides cardiorenal protection beyond simple blood pressure lowering, creating a stronger competitive advantage.

+0.50

The drug showed a favorable safety profile with low rates of confirmed hyperkalemia (2.4% in CKD participants and 0% in non-CKD participants). — Low rates of hyperkalemia are critical for aldosterone-targeting drugs, as this side effect is a common cause of clinical failure or restrictive labeling.

+0.40

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

What matters in this story

Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– HBSS

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

What matters in this story

Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– HBSS

Sentiment in this article

Relationships in this article

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

Mineralys' pill cuts blood pressure in kidney disease patients

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

GOSSAMER BIO DEADLINE MONDAY JUNE 1st: Bragar Eagel & Squire, P.C. Urges Gossamer Bio, Inc. (NASDAQ:GOSS) Investors with Large Losses to Contact the Firm Before Monday June 1st

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

What matters in this story

Next reads from the same story arc

Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– HBSS

Mineralys Therapeutics Presents New Data from the Phase 3 Launch-HTN Trial of Lorundrostat in Participants with Hypertension and Chronic Kidney Disease at European Meeting on Hypertension and Cardiovascular Protection (ESH 2026)

What matters in this story

Next reads from the same story arc

Gossamer Bio, Inc. (GOSS) Faces Securities Class Action Amid 80% Drop On Phase 3 PROSERA Trial Failure– HBSS

Sentiment in this article

Relationships in this article

Analytical profile by cluster

Top impact dimensions

Most positively impacted

Most negatively impacted

Mineralys' pill cuts blood pressure in kidney disease patients

ROSEN, A RANKED AND LEADING LAW FIRM, Encourages Immutep Ltd. Investors to Secure Counsel Before Important Deadline in Securities Class Action - IMMP

Transactions with Shares and Linked Securities in Genmab A/S Made by Managerial Employees and Their Closely Associated Persons

Corcept Presents New Data at ASCO 2026: Lifyorli™ Overall Survival Across All Subgroups of Patients with Platinum-Resistant Ovarian Cancer, Including Those with Recent Taxane Exposure

GOSSAMER BIO DEADLINE MONDAY JUNE 1st: Bragar Eagel & Squire, P.C. Urges Gossamer Bio, Inc. (NASDAQ:GOSS) Investors with Large Losses to Contact the Firm Before Monday June 1st